2. Search Result
Search Result
Results for "

glycogen synthesis

" in MedChemExpress (MCE) Product Catalog:

24

Inhibitors & Agonists

2

Biochemical Assay Reagents

3

Peptides

8

Natural
Products

4

Isotope-Labeled Compounds

1

Click Chemistry

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15424
    5-Iodotubercidin
    10+ Cited Publications

    NSC 113939; 5-ITu

    		 Adenosine Kinase Cancer
    5-Iodotubercidin (NSC 113939), an ATP mimetic, is a potent adenosine kinase inhibitor with an IC50 of 26 nM. 5-Iodotubercidin (NSC 113939) initiates glycogen synthesis in isolated hepatocytes by causing inactivation of phosphorylase and activation of glycogen synthase. 5-Iodotubercidin (NSC 113939) also inhibits CK1, insulin receptor tyrosine kinase, phosphorylase kinase, PKA, CK2, PKC and Haspin .
    5-Iodotubercidin
  • HY-N0143
    Phlorizin
    Maximum Cited Publications
    15 Publications Verification

    Floridzin

    		 Caspase JAK GLUT STAT Apoptosis Bacterial SGLT mTOR Akt NF-κB PI3K DNA/RNA Synthesis Infection Neurological Disease Metabolic Disease Cancer
    Phlorizin (Floridzin) is an orally active non-selective sodium-glucose cotransporter (SGLT) inhibitor, with an IC50 of 0.04 μM and a Ki of 39 nM against hSGLT2, and an IC50 of 0.17 μM and a Ki of 0.31 μM against hSGLT1. Phlorizin promotes GLUT4 translocation, inhibits gluconeogenesis and promotes glycogen synthesis by activating the PI3K/Akt/mTOR pathway. Phlorizin reduces DNA damage and apoptosis (apoptosis) by inhibiting the NF-κB inflammatory pathway. Phlorizin induces apoptosis via activating the Caspase pathway by antagonizing the JAK/STAT3 and PCK pathways. Phlorizin also exhibits antibacterial, anti-inflammatory and neuroprotective activities .
    Phlorizin
  • HY-112537
    D-Glucose 6-phosphate
    4 Publications Verification

    		 Endogenous Metabolite mTOR Cardiovascular Disease Metabolic Disease
    D-Glucose 6-phosphate is a key central node metabolite in glucose metabolism. It serves as the initiating metabolite for glycolysis and the pentose phosphate pathway, as well as a substrate for glycogen synthesis. D-Glucose 6-phosphate acts as a metabolic stress signal, which activates the mTOR pathway to promote protein synthesis, especially when phosphoglucose isomerase (PGI) is inhibited, thereby participating in cardiac remodeling processes. D-Glucose 6-phosphate can be used in research related to non-insulin-dependent diabetes mellitus and heart failure .
    D-Glucose 6-phosphate
  • HY-42680
    D-Tagatose

    D-(-)-Tagatose

    		 Endogenous Metabolite Metabolic Disease Inflammation/Immunology Cancer
    D-Tagatose (D-(-)-Tagatose) is a natural low-calorie rare sugar. D-Tagatose inhibits the activities of sucrase, maltase and intestinal disaccharidases, reduces the digestion of sucrose and starch, and blocks the absorption of sucrose, maltose and glucose. D-Tagatose promotes glucokinase activity and inhibits glycogen phosphorylase activity via tagatose-1-phosphate, regulates the synthesis and decomposition of hepatic glycogen, reduces postprandial and fasting blood glucose levels, and improves hyperinsulinemia. D-Tagatose regulates lipid profiles, stimulates GLP-1 secretion, and exhibits prebiotic effects. D-Tagatose is a bulking sweetener. D-Tagatose can be used in research related to diabetes, hyperlipidemia, dental caries, atherosclerosis and type 2 diabetes .
    D-Tagatose
  • HY-41121
    Boc-L-Ala-OH
    1 Publications Verification

    Boc-Ala-OH

    		 Amino Acid Derivatives Cancer
    Boc-L-Ala-OH (Boc-Ala-OH) is a single N-protected amino acid ligand and a protected L-alanine derivative. Boc-L-Ala-OH promotes Pd (II)-catalyzed enantioselective C-H alkenylation and kinetic resolution. Boc-L-Ala-OH serves as a coupling reagent for the synthesis of liver-targeted glycogen phosphorylase inhibitors and P6A metabolites, and also acts as a negative control in synthesis studies of betulinic acid amino acid esters. Boc-L-Ala-OH is applicable to research on epidermoid squamous cell carcinoma .
    Boc-L-Ala-OH
  • HY-112537S1
    D-Glucose 6-Phosphate-13C6 (disodium xhydrate)

    		Isotope-Labeled Compounds Endogenous Metabolite mTOR Cardiovascular Disease Metabolic Disease
    D-Glucose 6-Phosphate- 13C6 disodium xhydrate is a 13C-labeled D-Glucose 6-phosphate disodium xhydrate. D-Glucose 6-phosphate disodium xhydrate is a key central node metabolite in sugar metabolism, serving as the initial metabolite of glycolysis and pentose phosphate pathway, and also a substrate for glycogen synthesis. D-Glucose 6-phosphate disodium xhydrate can act as a metabolic stress signal, especially when phosphoglucomutase (PGI) is inhibited, activating the mTOR pathway, promoting protein synthesis, and thereby participating in the remodeling process of the heart. D-Glucose 6-phosphate disodium xhydrate can be used in research related to non-insulin-dependent diabetes and heart failure.
    D-Glucose 6-Phosphate-13C6 (disodium xhydrate)
  • HY-N7676
    Marein
    3 Publications Verification

    		 AMPK HDAC Cardiovascular Disease Neurological Disease Metabolic Disease
    Marein has the neuroprotective effect due to a reduction of damage to mitochondria function and activation of the AMPK signal pathway. Marein improves insulin resistance induced by high glucose in HepG2 cells through CaMKK/AMPK/GLUT1 to promote glucose uptake, through IRS/Akt/GSK-3β to increase glycogen synthesis, and through Akt/FoxO1 to decrease gluconeogenesis. Marein is a HDAC inhibitor with an IC50 of 100 μM. Marein has beneficial antioxidative, antihypertensive, antihyperlipidemic and antidiabetic effects .
    Marein
  • HY-N0143A
    Phlorizin dihydrate
    10+ Cited Publications

    Floridzin dihydrate

    		 SGLT PI3K Akt GLUT NF-κB JAK STAT Caspase Apoptosis DNA/RNA Synthesis mTOR Bacterial Infection Neurological Disease Metabolic Disease Cancer
    Phlorizin (Floridzin) dihydrate is an orally active non-selective sodium-glucose cotransporter (SGLT) inhibitor, with an IC50 of 0.04 μM and a Ki of 39 nM against hSGLT2, and an IC50 of 0.17 μM and a Ki of 0.31 μM against hSGLT1. Phlorizin dihydrate promotes GLUT4 translocation, inhibits gluconeogenesis and promotes glycogen synthesis by activating the PI3K/Akt/mTOR pathway. Phlorizin dihydrate reduces DNA damage and apoptosis (apoptosis) by inhibiting the NF-κB inflammatory pathway. Phlorizin dihydrate induces apoptosis via activating the Caspase pathway by antagonizing the JAK/STAT3 and PCK pathways. Phlorizin dihydrate also exhibits antibacterial, anti-inflammatory and neuroprotective activities .
    Phlorizin dihydrate
  • HY-P4685
    (Sar1,Ile4,8)-Angiotensin II

    		Angiotensin Receptor Metabolic Disease
    (Sar1,Ile4,8)-Angiotensin II is a functionally selective angiotensin II type 1 receptor (AT1R) agonist. (Sar1,Ile4,8)-Angiotensin II potentiates insulin-stimulated insulin receptor (IR) signaling and glycogen synthesis. (Sar1,Ile4,8)-Angiotensin II potentiates insulin-stimulated phosphorylation of Akt and GSK3α/β .
    (Sar1,Ile4,8)-Angiotensin II
  • HY-112537S2
    D-Glucose 6-phosphate-13C

    		Isotope-Labeled Compounds Endogenous Metabolite mTOR Others
    D-Glucose 6-phosphate- 13C is 13C labeled D-Glucose 6-phosphate (HY-112537). D-Glucose 6-phosphate is a key central node metabolite in glucose metabolism. It serves as the initiating metabolite for glycolysis and the pentose phosphate pathway, as well as a substrate for glycogen synthesis. D-Glucose 6-phosphate acts as a metabolic stress signal, which activates the mTOR pathway to promote protein synthesis, especially when phosphoglucose isomerase (PGI) is inhibited, thereby participating in cardiac remodeling processes. D-Glucose 6-phosphate can be used in research related to non-insulin-dependent diabetes mellitus and heart failure.
    D-Glucose 6-phosphate-13C
  • HY-15424R
    5-Iodotubercidin (Standard)

    NSC 113939 (Standard); 5-ITu (Standard)

    		 Adenosine Kinase Reference Standards Cancer
    5-Iodotubercidin (Standard) is the analytical standard of 5-Iodotubercidin. This product is intended for research and analytical applications. 5-Iodotubercidin (NSC 113939), an ATP mimetic, is a potent adenosine kinase inhibitor with an IC50 of 26 nM. 5-Iodotubercidin (NSC 113939) initiates glycogen synthesis in isolated hepatocytes by causing inactivation of phosphorylase and activation of glycogen synthase. 5-Iodotubercidin (NSC 113939) also inhibits CK1, insulin receptor tyrosine kinase, phosphorylase kinase, PKA, CK2, PKC and Haspin .
    5-Iodotubercidin (Standard)
  • HY-W400427
    α-D-Glucose-1-phosphate

    		Biochemical Assay Reagents Others
    α-D-Glucose-1-phosphate is an important intermediate in sugar metabolism, functioning as a glycosyl donor in glycosyl transfer reactions and participating in glycogen synthesis and degradation through the action of phosphorylases .
    α-D-Glucose-1-phosphate
  • HY-112537A
    D-Glucose 6-phosphate dipotassium

    		Endogenous Metabolite mTOR Cardiovascular Disease Metabolic Disease
    D-Glucose 6-phosphate dipotassium is a key central node metabolite in glucose metabolism. It serves as the initiating metabolite for glycolysis and the pentose phosphate pathway, as well as a substrate for glycogen synthesis. D-Glucose 6-phosphate dipotassium acts as a metabolic stress signal, which activates the mTOR pathway to promote protein synthesis, especially when phosphoglucose isomerase (PGI) is inhibited, thereby participating in cardiac remodeling processes. D-Glucose 6-phosphate dipotassium can be used in research related to non-insulin-dependent diabetes mellitus and heart failure .
    D-Glucose 6-phosphate dipotassium
  • HY-42680S1
    D-Tagatose-13C-1

    D-(-)-Tagatose-13C-1

    		 Isotope-Labeled Compounds Endogenous Metabolite Cardiovascular Disease Metabolic Disease Cancer
    D-Tagatose- 13C-1 is the 13C labeled D-Tagatose (HY-42680). D-Tagatose (D-(-)-Tagatose) is a natural low-calorie rare sugar. D-Tagatose inhibits the activities of sucrase, maltase and intestinal disaccharidases, reduces the digestion of sucrose and starch, and blocks the absorption of sucrose, maltose and glucose. D-Tagatose promotes glucokinase activity and inhibits glycogen phosphorylase activity via tagatose-1-phosphate, regulates the synthesis and decomposition of hepatic glycogen, reduces postprandial and fasting blood glucose levels, and improves hyperinsulinemia. D-Tagatose regulates lipid profiles, stimulates GLP-1 secretion, and exhibits prebiotic effects. D-Tagatose is a bulking sweetener. D-Tagatose can be used in research related to diabetes, hyperlipidemia, dental caries, atherosclerosis and type 2 diabetes.
    D-Tagatose-13C-1
  • HY-42680R
    D-Tagatose (Standard)

    D-(-)-Tagatose (Standard)

    		 Reference Standards Endogenous Metabolite Cardiovascular Disease Metabolic Disease Cancer
    D-Tagatose (Standard) is the analytical standard of D-Tagatose (HY-42680). This product is intended for research and analytical applications. D-Tagatose (D-(-)-Tagatose) is a natural low-calorie rare sugar. D-Tagatose inhibits the activities of sucrase, maltase and intestinal disaccharidases, reduces the digestion of sucrose and starch, and blocks the absorption of sucrose, maltose and glucose. D-Tagatose promotes glucokinase activity and inhibits glycogen phosphorylase activity via tagatose-1-phosphate, regulates the synthesis and decomposition of hepatic glycogen, reduces postprandial and fasting blood glucose levels, and improves hyperinsulinemia. D-Tagatose regulates lipid profiles, stimulates GLP-1 secretion, and exhibits prebiotic effects. D-Tagatose is a bulking sweetener. D-Tagatose can be used in research related to diabetes, hyperlipidemia, dental caries, atherosclerosis and type 2 diabetes.
    D-Tagatose (Standard)
  • HY-42680S
    D-Tagatose-13C

    D-(-)-Tagatose-13C

    		 Isotope-Labeled Compounds Endogenous Metabolite Cardiovascular Disease Metabolic Disease Cancer
    D-Tagatose- 13C is the 13C labeled D-Tagatose (HY-42680). D-Tagatose (D-(-)-Tagatose) is a natural low-calorie rare sugar. D-Tagatose inhibits the activities of sucrase, maltase and intestinal disaccharidases, reduces the digestion of sucrose and starch, and blocks the absorption of sucrose, maltose and glucose. D-Tagatose promotes glucokinase activity and inhibits glycogen phosphorylase activity via tagatose-1-phosphate, regulates the synthesis and decomposition of hepatic glycogen, reduces postprandial and fasting blood glucose levels, and improves hyperinsulinemia. D-Tagatose regulates lipid profiles, stimulates GLP-1 secretion, and exhibits prebiotic effects. D-Tagatose is a bulking sweetener. D-Tagatose can be used in research related to diabetes, hyperlipidemia, dental caries, atherosclerosis and type 2 diabetes.
    D-Tagatose-13C
  • HY-113002
    α-D-Glucose 1,6-bisphosphate

    		Phosphomannose Isomerase (PMI) Infection Metabolic Disease
    α-D-Glucose 1,6-bisphosphate is an activator of PMM2 and phosphoglucomutase. α-D-Glucose 1,6-bisphosphate regulates glycogen metabolism, glycolysis, amino sugar synthesis, as well as the formation of bacterial cell walls and capsules. α-D-Glucose 1,6-bisphosphate can be used in studies related to pmm2-cdg (cdg-1a or Jaeken syndrome) .
    α-D-Glucose 1,6-bisphosphate
  • HY-N3628
    Coronarin A

    		mTOR Ribosomal S6 Kinase (RSK) Metabolic Disease Inflammation/Immunology
    Coronarin A is an orally active natural compound that inhibits mTORC1 and S6K1 to increase IRS1 activity. Coronarin A shows anti-inflammatory activity and can also be used for type 2 diabetes mellitus research .
    Coronarin A
  • HY-N0143R
    Phlorizin (Standard)

    Floridzin (Standard)

    		 Reference Standards Caspase JAK GLUT STAT Apoptosis Bacterial SGLT mTOR Akt NF-κB PI3K DNA/RNA Synthesis Infection Neurological Disease Metabolic Disease Cancer
    Phlorizin (Floridzin) (Standard) is the analytical standard of Phlorizin. This product is intended for research and analytical applications. Phlorizin is an orally active non-selective sodium-glucose cotransporter (SGLT) inhibitor, with an IC50 of 0.04 μM and a Ki of 39 nM against hSGLT2, and an IC50 of 0.17 μM and a Ki of 0.31 μM against hSGLT1. Phlorizin promotes GLUT4 translocation, inhibits gluconeogenesis and promotes glycogen synthesis by activating the PI3K/Akt/mTOR pathway. Phlorizin reduces DNA damage and apoptosis (apoptosis) by inhibiting the NF-κB inflammatory pathway. Phlorizin induces apoptosis via activating the Caspase pathway by antagonizing the JAK/STAT3 and PCK pathways. Phlorizin also exhibits antibacterial, anti-inflammatory and neuroprotective activities .
    Phlorizin (Standard)
  • HY-P2032
    Cyclochlorotine

    		Endogenous Metabolite Infection Cancer
    Cyclochlorotine is a mycotoxin that can be extracted from the yellow rice infectant Penicillium islandicum Sopp. Cyclochlorotine promotes glycogenolysis, inhibits glycogen synthesis, affects fat synthesis and protein synthesis in liver cells. Cyclochlorotine exhibits chronic toxicity in liver that induces liver fibrosis and cirrhosis in mouse models. Cyclochlorotine exhibits carcinogenicity .
    Cyclochlorotine
  • HY-E71212
    α-1,4-Glucan-protein synthase (ADP-forming)

    		Biochemical Assay Reagents Others
    α-1,4-Glucan-protein synthase (ADP-forming) (EC 2.4.1.113) builds up α-1,4-Glucan chains covalently bound to protein, thus acting as an initiator of glycogen synthesis.
    α-1,4-Glucan-protein synthase (ADP-forming)
  • HY-183148
    NAMPT activator-10

    		NAMPT ATP Synthase Neurological Disease
    NAMPT activator-10 (Compound B11) is an orally active NAMPT activator with a target Kd value of 0.64 μM. NAMPT activator-10 activates the rate-limiting enzyme in NAD + biosynthesis and promotes intracellular NAD + synthesis. NAMPT activator-10 reduces lactate accumulation, enhances glycogen storage in the liver and muscle, increases tissue ATP production, improves exercise endurance and muscle strength, and exerts a protective effect against fatigue-induced muscle damage in mouse fatigue models. NAMPT activator-10 can be used in studies related to muscle fatigue .
    NAMPT activator-10
  • HY-182978
    Pomalidomide-C3-O-C4-O-C3-NH2

    		E3 Ligase Ligand-Linker Conjugates Others
    Pomalidomide-C3-O-C4-O-C3-NH2 is an E3 ligase ligand-linker conjugate that contains Pomalidomide (HY-10984). Pomalidomide-C3-O-C4-O-C3-NH2 can be used for the synthesis of PROTACs targeting glycogen synthase kinase 3β (GSK-3β), such as PROTAC GSK-3β Degrader-1 (HY-149845) .
    Pomalidomide-C3-O-C4-O-C3-NH2
  • HY-W207669
    Centpiperalone

    		Insulin Receptor Metabolic Disease
    Centpiperalone is an orally active hypoglycemic agent. Centpiperalone mainly achieves its hypoglycemic effect by promoting the release of insulin by pancreatic β cells. Centpiperalone can effectively lower blood sugar levels in both normal and diabetic animals. Centpiperalone can be used in research on diabetes .
    Centpiperalone

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: